YG 1699
Alternative Names: ABSK101; YG-1699Latest Information Update: 04 Aug 2023
At a glance
- Originator Youngene Therapeutics
- Class Antifibrotics; Antihyperglycaemics; Heart failure therapies; Small molecules
- Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus
- Phase I Diabetes mellitus; Diabetic nephropathies; Heart failure
- Preclinical Cystic fibrosis
Most Recent Events
- 23 Jun 2023 Pharmacodynamic and pharmacokinetic data from a preclinical trial in Diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ASAD-2023)
- 17 Jan 2023 Phase-I clinical trials in Diabetic nephropathies in China (PO) (Youngene Therapeutics pipeline, January 2023)
- 17 Jan 2023 Phase-I clinical trials in Heart failure in China (PO) (Youngene Therapeutics pipeline, January 2023)